The prevalence of type 2 diabetes (T2D) is increasing, and owing to the aging population, the number of older adults with T2D is growing rapidly. By virtue of their age, older adults are likely to have been living with the disease longer than their younger counterparts. This, coupled with differences in T2D pathophysiology between younger and older patients, means that older adults often require advancement of treatment from basal insulin. However, older adults with T2D represent a heterogeneous population, for whom the goals of treatment are complex, and overtreatment can increase the risk of complications. These factors highlight the need for individualized glycemic targets and therapeutic strategies. In this roundtable, the authors discuss the management of older adults with T2D--a large patient population who often require treatment simplification.
Video 1: Introduction
Video 2: Unique Pathophysiology of Type 2 Diabetes in Older Adults
Video 3: Treatment Considerations When Managing Older Adults With Type 2 Diabetes
Video 4: Advancement of Basal Insulin Therapy: Options for Older Adults
Video 5: Simplification and/or Deintensification of Complex Insulin Regimens
Video 6: Practical Tips for Choosing Appropriate Therapy for Older Adults With Type 2 Diabetes
This peer-reviewed publication was developed in adherence with Good Publication Practice (GPP3) guidelines. All authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship and have disclosed all potential conflicts of interest.
Mark Corriere, MD, FACP
Speakers’ bureau for AbbVie, AstraZeneca, Bayer, Eli Lilly and Company, Novo Nordisk, Sanofi, Zealand
Brian Burtch, MD
Speakers’ bureau for Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Sanofi
Naushira Pandya, MD, CMD, FACP
Speaker for Eli Lilly and Company
This digital publication was funded by Sanofi US. The authors received writing and editorial support in the preparation of the material provided by Helen Jones, PhD, of Evidence Scientific Solutions, funded by Sanofi US.